

# Merck's commitment to American manufacturing, R&D and economic growth



For more than 130 years, Merck, a leading American biopharmaceutical company, has been committed to saving and improving lives by developing and delivering life-changing medicines and vaccines to treat diseases in both humans and animals.

Headquartered in the United States, we remain committed to continuously bolstering the American economy and enhancing the communities where we operate through substantial investments in innovation in U.S. manufacturing and research and development (R&D).

Since the enactment of the 2017 tax reform law, Merck has accelerated its commitment to U.S. innovation and manufacturing. Notably, we've invested over **\$12 billion in U.S. manufacturing since 2017** and more than **\$81 billion in U.S.-based R&D** since 2018, supporting tens of thousands of American jobs. This year alone, we announced nearly **\$6 billion in manufacturing investments** across North Carolina, Delaware, Kansas and Virginia, which will create more than **1,600 new jobs** in the U.S. through 2030 and beyond.

Beginning in 2025, Merck will invest more than **\$70 billion** to expand domestic manufacturing and research and development—not including any future business development transactions in R&D—to drive its long-term growth and strengthen the status of the U.S. as a global leader in biopharmaceutical innovation. **By 2030 we will have the capability to manufacture all of our small molecule products in the U.S.**

Additionally, we will continue relocating several manufacturing operations and jobs from overseas to the U.S., including production of KEYTRUDA in 2026 with the intent of having KEYTRUDA for American patients made in America.

We also boast a U.S.-based Animal Health network of sites where we manufacture a broad portfolio of vaccines and large molecule therapies made end to end in the U.S.

All these efforts to stimulate American economic growth allow for the domestic production and distribution of U.S. medicines and vaccines to protect patients while generating:

More than

## 8,500

full-time U.S.-based high-paying, meaningful employment opportunities — *an increase of nearly 35% since 2018 as a result of the tax reform law*

Upwards of

## 48,000

construction opportunities, with more than 48,000 forecast for 2025-2029

An average of

## 1,600

contract positions per year since 2019

We plan to invest **\$3 billion** in biologics and small molecule manufacturing sites/capabilities in the U.S., expected to create more than **800 jobs**, while also investing **\$3.5+ billion** in our Rahway headquarters, which will create roughly 1,000 jobs across research and clinical manufacturing.



# U.S. manufacturing by the numbers

In 2026, we plan to bring **KEYTRUDA** manufacturing operations for U.S. patients to the U.S.

**ENFLONISIA** is 100% U.S. supply chain.

We are the sole supplier of **TICE BCG**.

## U.S. FINISHED GOODS

More than

# 94%

of Merck's U.S. saleable units are packaged at facilities in North Carolina and Pennsylvania, with additional support from U.S. contract manufacturers.

## VACCINE MANUFACTURING

Over

# 85%

of vaccine drug substances are produced in the U.S. for both domestic and global markets, reflecting our strong domestic manufacturing focus.

## VACCINE FORMULATION AND PACKAGING

More than

# 98%

of vaccine formulation, filling or packaging for the U.S. market occurs at domestic sites, with about **50%** of international demand also fulfilled from U.S. facilities.

# Key Investments

## DURHAM, NORTH CAROLINA (MARCH 2025)

### \$1 billion

investment generating nearly **400** full-time jobs and roughly **4,000** construction jobs.

## DE SOTO, KANSAS (MAY 2025)

### \$895 million

investment in a 200,000 sq. ft. manufacturing facility project will expand filling and freeze dryer capacity for large molecule vaccines and biologic products for Merck Animal Health; site preparation and facility design will start immediately, creating **2,500** construction jobs; commercial manufacturing is expected to begin in 2030, creating more than **200** full-time roles.

## ELKTON, VIRGINIA (OCTOBER 2025)

### \$3 billion

investment in a 400,000 sq. ft. state-of-the-art pharmaceutical center of excellence at our Elkton, VA site. The expansion will include both Active Pharmaceutical Ingredient (API) and Drug Product investment supporting small molecule manufacturing and testing. The project will create roughly **500** full-time manufacturing jobs as well as **8,000** construction jobs.

## WILMINGTON, DELAWARE (APRIL 2025)

A more than

### \$1 billion

investment in a **470,000 sq. ft.** biologics commercialization and launch facility generating approximately **500** full-time jobs and roughly **4,000** construction jobs.

Potential further expansion of the site would create an additional **1,500** full-time roles and **26,000** construction jobs.

### Future manufacturing site for KEYTRUDA for U.S. patients

#### *Significant investment*

Bringing the manufacturing of KEYTRUDA to Delaware marks an unparalleled investment.

#### *Strong U.S. footprint*

By producing KEYTRUDA in the U.S., as well as numerous future biologic products, we are reaffirming our commitment to a strong U.S. footprint that supports the President's economic agenda

#### *Patient impact*

Manufacturing in the U.S. brings the immunotherapy closer to the American patients who rely on KEYTRUDA.

#### *Trusted partner*

Merck is a constructive partner that is willing to participate in the policy and pressing conversations that have significant implications for our operating environment.



# Impact

## U.S. CAPITAL INVESTMENTS

Invested more than

**\$12 billion**

in U.S. capital, dedicated to expanding American manufacturing and R&D capabilities, and plans to invest more than **\$12 billion** over the next five years.

## OVERALL JOB CREATION

### **Full-time:**

Created over

**8,500**

U.S.-based, full-time jobs — a **nearly 35% growth** since 2018.

### **Trade/ construction:**

Hired more than

**48,000**

workers from 2018 - 2024; forecasting **an additional 48,000 workers** from 2025 - 2029.

### **Contract:**

Averaged

**1,600**

contract positions per year over the past five years.

## AVERAGE ANNUAL EARNINGS

Forecasting

**\$1.4 billion**

average annual earnings for U.S.-based manufacturing employees from 2025 - 2028.



# State snapshot\*

Merck continues to invest in manufacturing and R&D capabilities across the country. We are committed to creating more high-paying, meaningful job opportunities within the United States, ensuring domestic production and distribution of U.S. medicines and vaccines and supporting the communities where we operate through philanthropic contributions, job training programs and various partnerships.

Merck's U.S. manufacturing headcount increased by 1,700 full-time employees between 2018 and 2024 driven by continued investment in our West Point, Pennsylvania, Elkton, Virginia, and Durham and Wilson, North Carolina sites primarily in the vaccines space. Continued investment in these sites, as well as new sites for biologics in Delaware (500 employees and a potential 1,500 more) and for small molecules in Virginia (500 employees), will drive incremental job creation. Offsetting these potential future increases are previously announced actions at Riverside, Pennsylvania, Elkton, Virginia (antibiotics only) and Las Piedras, Puerto Rico.

## California

### TOTAL IN STATE

Invested  
**\$236M+**  
(2018-2024)  
and expecting  
**\$14M+** (2025-2029)

### SOUTH SAN FRANCISCO

Invested  
**\$230M+**  
(2018-2024)  
and expecting  
**\$12M+** (2025-2029)

### SAN DIEGO

Invested  
**\$3M+**  
(2018-2024)  
and expecting  
**\$2M+** (2025-2029)

### PALO ALTO

Invested  
**\$3M+**  
(2018-2024)

**512**

jobs created across  
the state (2018-2025)



# Delaware

## TOTAL IN STATE

Invested  
**\$256M+**  
(2018-2024)  
and expecting  
**\$1B+** (2025-2029)

**82**  
jobs created across  
the state (2018-2025)

## MILLSBORO

Invested  
**\$207M+**  
(2018-2024)  
and expecting  
**\$85M+** (2025-2029)

## WILMINGTON

Invested  
**\$49M**  
(2018-2024)  
and expecting  
**\$1B+** (2025-2029)

# Iowa

## AMES/ TOTAL IN STATE

Invested  
**\$7M+**  
(2018-2024)  
and expecting  
**\$2M+** (2025-2029)

**6**  
jobs created across  
the state (2018-2025)

# Kansas

## DE SOTO/ TOTAL IN STATE

Invested  
**\$242M+**  
(2018-2024)  
and expecting  
**\$804M+** (2025-2029)

**136**  
jobs created across  
the state (2018-2025)

# Louisiana

## BATON ROUGE/ TOTAL IN STATE

Invested  
**\$2M+**  
(2018-2024)  
and expecting  
**\$1M+** (2025-2029)

# Massachusetts

## TOTAL IN STATE

Invested

**\$169M+**

(2018-2024)

and expecting

**\$44M+** (2025-2029)

## BOSTON

Invested

**\$89M+**

(2018-2024)

and expecting

**\$21M+** (2025-2029)

## CAMBRIDGE

Invested

**\$80M+**

(2018-2024)

and expecting

**\$23M+** (2025-2029)

**278**

jobs created across  
the state (2018-2025)

# Minnesota

## WORTHINGTON/ TOTAL IN STATE

Invested

**\$18M+**

(2018-2024)

and expecting

**\$32M+** (2025-2029)

# Nebraska

## ELKHORN/ TOTAL IN STATE

Invested

**\$408M+**

(2018-2024)

and expecting

**\$275M+** (2025-2029)

**10**

jobs created across  
the state (2018-2025)

**124**

jobs created across  
the state (2018-2025)

# New Jersey

## TOTAL IN STATE

Invested  
**\$2.9B+**  
(2018-2024)  
and expecting  
**\$3.9B+** (2025-2029)

**3,642**  
jobs created across  
the state (2018-2025)

## RAHWAY

Invested  
**\$2.7B+**  
(2018-2024)  
and expecting  
**\$3.9B+** (2025-2029)

## KENILWORTH

Invested  
**\$129M**  
(2018-2024)

## MADISON

Invested  
**\$25M+**  
(2018-2024)

## WHITEHOUSE

Invested  
**\$20M+**  
(2018-2024)

## BRANCHBURG

Invested  
**\$2M+**  
(2018-2024)

# North Carolina

## TOTAL IN STATE

Invested  
**\$2.18B+**  
(2018-2024)  
and expecting  
**\$617M+** (2025-2029)

**513**  
jobs created across  
the state (2018-2025)

## DURHAM

Invested  
**\$1.85B+**  
(2018-2024)  
and expecting  
**\$304M+** (2025-2029)

## WILSON

Invested  
**\$316M+**  
(2018-2024)  
and expecting  
**\$313M+** (2025-2029)

## CHARLOTTE

Invested  
**\$9M+**  
(2018-2024)



# Pennsylvania

## TOTAL IN STATE

Invested  
**\$4.17B+**  
(2018-2024)  
and expecting  
**\$3.2B+** (2025-2029)

**2,169**  
jobs created across  
the state (2018-2025)

## WEST POINT

Invested  
**\$3.87B+**  
(2018-2024)  
and expecting  
**\$2.9B+** (2025-2029)

## NORTH WALES

Invested  
**\$95M+**  
(2018-2024)  
and expecting  
**\$157M+** (2025-2029)

## UPPER GWYNEDD

Invested  
**\$84M+**  
(2018-2024)  
and expecting  
**\$110M+** (2025-2029)

## RIVERSIDE

Invested  
**\$64M+**  
(2018-2024)

## SPRINGHOUSE

Invested  
**\$55M+**  
(2018-2024)

# Virginia

## ELKTON/ TOTAL IN STATE

Invested  
**\$1.48B+**  
(2018-2024) and expecting  
**\$3B+** (**\$1.5B+** 2025-2029  
with an additional **\$1.5B+**  
through mid-2030)

**309**  
jobs created across  
the state (2018-2025)

